<DOC>
	<DOC>NCT01836185</DOC>
	<brief_summary>The purpose of this study is to measure how much of the drug gets into the bloodstream and how long it takes the body to remove it when given to participants with hepatic (liver) impairment compared to participants with normal hepatic function. Information about any side effects that may occur will also be collected. This study will last approximately 28 days, not including screening.</brief_summary>
	<brief_title>A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<mesh_term>Evacetrapib</mesh_term>
	<criteria>Participants have given written informed consent approved by the ethical review board (ERB) governing the site Female participants should be of nonchildbearing potential Have a body mass index of 18 to 40 kilograms per square meter (kg/m^2) Healthy participants have normal hepatic function as determined by medical history, physical examination, and other screening procedures Individuals with hepatic impairment classified as ChildPugh score A, B, or C (mild, moderate, or severe impairment) Has had esophagus variceal bleeding within 3 months of checkin Have the need to take medications that may interfere with how the liver removes the drug Have evidence of cancer in the liver Consumes excessively large amounts of drinks with caffeine or alcohol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>